Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, May 13, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate at the upcoming investor conferences:

• UBS Global Healthcare Conference on Monday, May 20, at 8:30 AM EDT in New York City
• RBC Capital Markets Global Healthcare Conference on Tuesday, May 21, at 2:05 PM EDT in New York City
• Berenberg USA Conference on Wednesday, May 22, at 2:45 PM EDT in Tarrytown, NY

A live audio webcast of the UBS and RBC presentations will be posted under the investor relations section of Arena's website at www.arenapharm.com. A replay of the available presentations will be available for 30 days following the event.

About Arena PharmaceuticalsArena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Arena's proprietary pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility. Etrasimod (APD334), with potential utility in a broad range of immune and inflammatory conditions, is being evaluated in late-stage clinical programs in ulcerative colitis (UC) and Crohn's disease, as well as in programs for other indications such as atopic dermatitis. Arena is also evaluating olorinab (APD371) in a Phase 2 program for gastrointestinal pain. Arena continues to assess other earlier research and development stage drug candidates, including APD418 for decompensated heart failure.

Arena has additional license agreements and partnerships, including with United Therapeutics (ralinepag in a Phase 3 program for pulmonary arterial hypertension), Everest Medicines Limited (etrasimod in Greater China and select Asian countries), Boehringer Ingelheim International GmbH (undisclosed target – preclinical), Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ® – marketed product).

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These forward-looking statements may be accompanied by words such as "will," "driven to," "potentially," "potential," "being evaluated," "evaluating for," "assess for," or words of similar meaning, or they may be identified by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include, without limitation, statements about Arena's participation in upcoming investor conferences, audio webcasts of Arena's presentations, and Arena's drive, focus, goals, strategy, clinical and research and development programs, collaborations, and licenses. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include: the timing and outcome of research, development and regulatory review is uncertain; clinical and preclinical programs may not proceed at the time or in the manner expected or at all; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; and other risks related to developing and commercializing drugs; as well as those factors disclosed in Arena's filings with the Securities and Exchange Commission (SEC), including but not limited to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, which was filed with the SEC on May 9, 2019. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Corporate Contact:                                       Kevin R. LindArena Pharmaceuticals, Inc.Executive Vice President and Chief Financial Officer                                   [email protected]858.210.3636

Media Contact:Matt Middleman, MDLifeSci Public Relations[email protected]646.627.8384

View original content to download multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-participate-in-upcoming-investor-conferences-300848415.html

SOURCE Arena Pharmaceuticals, Inc.